Hepion Pharmaceuticals, Inc. (HEPA): Price and Financial Metrics
HEPA Price/Volume Stats
| Current price | $1.37 | 52-week high | $20.66 |
| Prev. close | $1.29 | 52-week low | $1.22 |
| Day low | $1.27 | Volume | 39,600 |
| Day high | $1.44 | Avg. volume | 73,373 |
| 50-day MA | $2.28 | Dividend yield | N/A |
| 200-day MA | $4.10 | Market Cap | 7.50M |
HEPA Stock Price Chart Interactive Chart >
Hepion Pharmaceuticals, Inc. (HEPA) Company Bio
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Latest HEPA News From Around the Web
Below are the latest news stories about HEPION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate HEPA as an investment opportunity.
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesRestructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market environment Cash runway extended into Q2 2025 EDISON, N.J., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcohol |
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitEDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston. Scott Campb |
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseFibroscan Liver Stiffness Absolute Change from Baseline (kPa) none - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - “These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat’s novel mechanism of action represents a fresh approach to the treatment of severe liver disease.” (Patrick Mayo, PhD, Hepion’s Senior VP, Clinica |
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatData release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it expects to release additional eff |
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model- Rencofilstat, but not sofosbuvir or velpatasvir, significantly suppressed tumor growth -EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced the publication of a new research study |
HEPA Price Returns
| 1-mo | -44.98% |
| 3-mo | -25.54% |
| 6-mo | -71.34% |
| 1-year | -90.15% |
| 3-year | -96.22% |
| 5-year | -99.14% |
| YTD | -57.72% |
| 2023 | -46.05% |
| 2022 | -73.66% |
| 2021 | -47.95% |
| 2020 | -59.14% |
| 2019 | -72.65% |
Loading social stream, please wait...